Product image of Imipenem E Cilastatina Steriscience (Cilastatin, Imipenem) supplied by GNH India

Imipenem E Cilastatina Steriscience

Active Ingredient:
Cilastatin, Imipenem
Origin:
EU

Imipenem E Cilastatina Steriscience (Cilastatin, Imipenem)

Imipenem, the active ingredient in Imipenem E Cilastatina Steriscience, is a carbapenem antibiotic presented as a powder for solution for injection for intravenous use. It treats serious bacterial infections in hospitalized patients, including intra‑abdominal, urinary, skin, and respiratory infections.

GNH India supplies Imipenem E Cilastatina Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Steriscience B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imipenem/cilastatin is used to treat severe bacterial infections across several organ systems.

  • Complicated intra‑abdominal infections: provides broad‑spectrum bacterial eradication in severe abdominal sepsis.
  • Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and cystitis.
  • Complicated skin and soft tissue infections: treats deep tissue infections and cellulitis caused by Gram‑negative and Gram‑positive bacteria.
  • Lower respiratory tract infections: effective against community‑acquired and hospital‑acquired pneumonia.
  • Febrile neutropenia: offers rapid bacterial coverage in immunocompromised patients with fever.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting the synthesis of bacterial cell walls and leading to cell lysis. Cilastatin, co‑administered, blocks renal dehydropeptidase I, preventing enzymatic degradation of imipenem and extending its antimicrobial activity in the body.

Side Effects

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Vomiting: occasional emesis after infusion.
  • Diarrhea: loose stools, generally self‑limiting.
  • Rash: mild skin erythema or pruritus.
  • Headache: transient headache during or after dosing.
  • Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects

  • Seizures: risk increases with high doses or renal impairment.
  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Clostridioides difficile‑associated diarrhea: possible severe colitis.
  • Stevens‑Johnson syndrome: rare severe skin reaction.
  • Renal toxicity: potential worsening of kidney function.
  • Neutropenia: marked reduction in neutrophil count.

Precautions & Warnings

Imipenem/cilastatin should be used with caution in patients with renal impairment, a history of seizures, or known hypersensitivity to beta‑lactams.

  • Renal function: adjust dose in patients with reduced creatinine clearance.
  • Seizure risk: avoid high doses in patients with CNS disorders.
  • Allergy: screen for penicillin or carbapenem allergy before administration.
  • Drug monitoring: observe for signs of superinfection or C. difficile colitis.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Store below 25°C: keep in original packaging, protect from moisture and light.

Avoid Interactions

Imipenem/cilastatin may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Valproic acid: concomitant use can lower valproate levels and precipitate seizures.
  • Other carbapenems: avoid simultaneous use to prevent additive toxicity.
  • Probenecid: may increase imipenem concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor electrolytes and renal function.
  • Anticoagulants: watch for altered INR or bleeding risk.
  • CNS depressants: observe for enhanced neurotoxic effects.

Frequently Asked Questions

Imipenem E Cilastatina is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, complicated skin and soft tissue infections, lower respiratory tract infections (both community‑acquired and hospital‑acquired), and febrile neutropenia in immunocompromised patients.

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin, included in the formulation, blocks renal dehydropeptidase I, preventing rapid degradation of imipenem and extending its antibacterial activity.

The dosage of Imipenem E Cilastatina is determined by the prescribing clinician based on infection severity, patient weight, renal function, and local antimicrobial guidelines. Only a qualified healthcare professional should set the dosing regimen.

Safety data for Imipenem/cilastatin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Imipenem, combined with cilastatin, offers a broad spectrum of activity against Gram‑negative, Gram‑positive, and anaerobic bacteria, similar to other carbapenems like meropenem. Differences lie in pharmacokinetics, stability, and specific bacterial coverage, with imipenem often chosen for its proven efficacy in mixed‑flora infections.

Store the powder for solution for injection below 25 °C in its original container, protected from moisture and light. Do not freeze. Reconstitute only with the diluent specified in the product label and use within the time frame recommended by the manufacturer.

The product is supplied as a sterile powder for solution for injection and is administered intravenously by a healthcare professional. The reconstituted solution is infused over a prescribed period, typically 30 minutes to 1 hour, depending on the clinical protocol.

Serious adverse events include seizures, especially in patients with renal impairment or CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare skin reactions like Stevens‑Johnson syndrome. Prompt medical attention is required if these occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or any carbapenem class should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, unless the prescriber determines the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin, Imipenem

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT